A few thoughts

Dear Agoracom Family,

I want to thank all of you for your patience with us over the past 48 hours and apologize for what was admittedly a botched launch of our new site.

As you can see, we have reverted back to the previous version of the site while we address multiple forum functionality flaws that inexplicably made their way into the launch.

To this end:

1.We have identified 8 fundamental but easily fixable flaws that will be corrected in the coming week, so that you can continue to use the forums exactly as you've been accustomed to.

2.Additionally we will also be implementing a couple of design improvements to "tighten up" the look and feel of the forums.

Sincerely,

George et al

Reply New Message

Prev Message Back To Forum Threaded View Next Message

bfw

Rank: Vice President [?]

Points: 840 [?]

Votes: 19 Score: 3.8 [?]

Your Vote:

Please Log In to Vote

Follow

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

A few thoughts

posted on Nov 16, 2019 12:52PM

Log in to use the IP Check tool ^[?]

The sensitivity analysis is very important as it was pre-specified. HR 0.79 with a p of 0.06 is a strong signal on 3 point MACE. An over 20% reduction is not far off from what AMRN achieved in 3 point MACE (yes I know the p value is just off significance).

The Forest Plot was very good as Don alluded to. No surprises there. A low placebo incidence and lack of effect on stroke sunk the trial result.

The heart failure data and the MACE data for CKD is impressive. Presenters will always downplay the results if the primary endpoint is missed but these were pre-specified.

Overall, I think the drug will make it to market at some point.

I expect Don to comment further on the CKD data Monday am as it is important and fits mechnistically with the alkaline phosphatase data.

Hopefully, the cognitive data will be good but I’m not expecting a home run there.

Overall, I think RVX needs a partner to go forward and hope Don has one lined up.

I’m not sure what the stock does Monday. I don’t think I was surprised by any of the results except for the CKD data looking good. The market was already fully aware we had a negative trial.

...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

A few thoughts